Savas’ presentation will include an update regarding the Company’s late-stage clinical development programs in Parkinson’s disease, Restless Legs Syndrome, atrial fibrillation, pharmacologic stress testing and diabetic foot ulcers. He will also discuss Aderis Pharmaceuticals’ development partnerships with Fujisawa Healthcare, Schwarz Pharma and King Pharmaceuticals, and the Company’s financial position. The Company recently received a $2 million milestone payment from Fujisawa Healthcare, and believes its experienced leadership team, adequate cash reserves and lack of debt position it to maximize multiple product development opportunities.

A recording of Aderis Pharmaceuticals’ presentation at the conference will be available through the Company’s web site at www.aderis.com. To access the recording, please click on the “News & Events” heading, follow the link to “Events” and scroll down to the CIBC conference information. The recording will be archived for 30 days.

Aderis Pharmaceuticals is a private, biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and renal disorders. The Company currently has four product candidates in six clinical development programs. Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma AG, for the development of rotigotine CDS, a proprietary dopamine agonist formulated as a once-a-day, continuous delivery, transdermal patch. Rotigotine is currently in Phase III trials for Parkinson’s disease and Phase II for the treatment of Restless Legs Syndrome. The Company also has alliances with Fujisawa Healthcare, Inc. and King Pharmaceuticals. Aderis Pharmaceuticals’ product pipeline includes small molecule, receptor agonists and antagonists for the treatment of Parkinson’s disease, Restless Legs Syndrome, atrial fibrillation, diabetic foot ulcers, the diagnosis and prognosis of coronary artery disease, and other cardiovascular and renal indications. Founded in 1994, Aderis Pharmaceuticals is headquartered in Hopkinton, Massachusetts and has research facilities in Richmond, Virginia.

Certain statements in this news release that are not historical fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Such statements include, but are not limited to, any statements relating to the Company’s development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties, including but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company’s drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug candidates that could slow or prevent product development or commercialization; the uncertainty of patent protection for the Company’s intellectual property or trade secrets; and the Company’s ability to obtain additional financing if necessary. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, some but not all of which may have been mentioned above.

Return to Press Releases

back to top